| Trial ID: | L0035 |
| Source ID: | NCT04990427
|
| Associated Drug: |
Clbs201
|
| Title: |
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Diseases
|
| Interventions: |
DRUG: CLBS201
|
| Outcome Measures: |
Primary: Serious Adverse Events, Proportion of patients with a treatment-emergent serious adverse event, 6 Months | Secondary: Estimated Glomerular Filtration Rate (eGFR), Change in eGFR from baseline, 6 Months|UACR & UPCR, Change in UACR \& UPCR from baseline, 6 Months
|
| Sponsor/Collaborators: |
Sponsor: Lisata Therapeutics, Inc.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
6
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2022-01-10
|
| Completion Date: |
2023-01-26
|
| Results First Posted: |
|
| Last Update Posted: |
2024-10-09
|
| Locations: |
Clinical Advancement Center, PLLC, San Antonio, Texas, 78212, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04990427
|
